# K020713: MS-30 Lateral Femoral Stem

- Pathway: 510(k) (Traditional)
- Applicant: Sulzer Orthopedics, Inc.
- Decided: May 14, 2002 after 70 days
- Product code: LZO (Prosthesis, Hip, Semi-Constrained, Metal/Ceramic/Polymer, Cemented Or Non-Porous, Uncemented)
- Device class: 2
- Regulation: 21 CFR 888.3353
- Recalls of this device: 1 (0 Class I)
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
No predicates in its family tree.
19 later devices descend from it; 3 cite it directly.
0 of 20 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- None. The FDA summary names its predicate without a number.
- (no number) MS-30 Femoral Stem, Centralizer: named in the summary without a submission number
- (no number) Howmedica Osteonics Exeter Hip Stem, Centralizer: named in the summary without a submission number
- (no number) Howmedica Osteonics Definitive Stem: named in the summary without a submission number
- (no number) Zimmer VerSys Hip Cemented CT Hip Stem, Centralizer: named in the summary without a submission number

## Most influential descendants
- K083558: Medacta Total Hip Prosthesis System - Quadra C (2009), 9 descendants of its own
- K040803: MS-30 Femoral Stem Standard and Lateral (2004), 8 descendants of its own
- K192827: Quadra-P (2020), 6 descendants of its own
- K133370: Remedy Hip Stem, Pegasus Hip Stem, Evolve Helios Hip Stem, Evolve Masters Hip Stem, Evolve Distal Centralizer, Evolve CE (2014), 5 descendants of its own
- K202730: Quadra-P (2020), 1 descendant of its own

## Recalls of this device
- Sep 4, 2012 · Class II · Z-0219-2013: Zimmer Inc., is initiating a correction to the patient labels of products manufactured before March 20I0 by the Zimmer GmbH production site in Winterthur, Switzerland, after receiving four complaints 

## Indications for use
The MS-30 Lateral Femoral Stem is intended for cemented use in treatment of the following: 1. Patient conditions of noninflammatory degenerative joint disease (NIDJD), e.g., avascular necrosis, osteoarthritis, and inflammatory joint disease (IJD), e.g., rheumatoid arthritis. 2. Those patients with failed previous surgery where pain, deformity, or dysfunction persists. 3. Revision of previously failed hip arthroplasty.

Source page: https://510kreport.com/device/K020713
Methodology: https://510kreport.com/methodology